LLY·Eli Lilly and Company
LLY|Analyst Targets
LLY|Company Info
LLY|Insider Trading
LLY|Fundamentals
LLY|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $7.16 | - | - |
| Q2'26 | $6.07 | $8.38 | +38.1% |
| Q1'26 | $6.79 | $8.55 | +25.9% |
| Q4'25 | $6.74 | $7.54 | +11.9% |
| Q3'25 | $5.89 | $7.02 | +19.2% |
| Q2'25 | $5.59 | $6.31 | +12.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $22.7B | - | - |
| Q2'26 | $20.9B | $23.0B | +9.8% |
| Q1'26 | $17.8B | $19.8B | +11.1% |
| Q4'25 | $18.1B | $19.3B | +6.4% |
| Q3'25 | - | $17.6B | - |
| Q2'25 | - | $15.6B | - |
LLY|Monthly Returns
Market Data
LLY Stock Snapshot
- Market cap
- 1.14T
- P/E ratio
- 42.6
- Day range
- $1213.76 – $1275.88
- News sentiment
- 57/100 · Neutral
- Analyst target
- $1328.05 (+6.0%)
- Consensus
- Buy · 39 analysts
Trend, momentum and range position line up bullish on LLY at the moment. Positioning shifts among large allocators, not retail flow, set the tone for a name this size.
Behaviour On Record
What LLY's own history says about today's numbers
- Realized volatility (21d)
- 25.2% 57th pct
- Below its peak
- -2.2%
- vs 200-day average
- +16.1%
- Up days (1y)
- 50%
Eli Lilly and Company is currently running 25.2% annualised volatility over the last 21 sessions. Measured against LLY's own 13 years of daily returns rather than a market-wide average, that is the 57th percentile — close to its own typical level, against a typical reading of 23.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
LLY is trading -2.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.0%, and the deepest was -32.6% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +16.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 67th percentile — a somewhat wider gap than its own norm. Over the past year LLY closed higher on 50% of sessions, and it is currently 2 sessions into a rising streak.
On October specifically: over 14 years of records, LLY finished the month higher 9 of 14 times, with a median return of +1.9% and an average of +1.0%. Its strongest month historically has been June at +5.6% on average, its weakest July at -0.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: LLY has opened more than 2% away from the prior close in 72 of 3,268 sessions (2.2% of the time), with the largest gaps running +11.5% and -5.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, LLY moved an average of 3.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.0% and a largest of -6.1%.
All figures computed from 3,269 daily closes between 2013-10-16 and 2026-10-15, split-adjusted, recomputed daily. Percentiles are against LLY's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of LLY's sector?
Eli Lilly and Company sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #1 of 12
- Sector state
- Leading
- Sector rotation score
- 100
Analyst Rating Changes
Are analysts turning bullish or bearish on LLY?
RBC Capital most recently reiterated its rating on Eli Lilly and Company to Outperform on Oct 12, 2026 with a price target of $1500. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- RBC Capital — Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Earnings Release, Scored
What did Eli Lilly and Company's latest earnings release say?
Most important lines
- 1
Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion and raised underlying non-GAAP EPS guidance for the full year by $2.78 at the midpoint, which was more than offset by $3.03 of acquired IPR&D charges from Q2 business development activity, resulting in an updated range of $35.50 to $36.50.
Guidance raisedNew this quarter - 2
"Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance," said David A. Ricks, Lilly chair and CEO.
Guidance raised - 3
In addition to updates to Revenue and Performance Margin guidance, EPS guidance has been adjusted to reflect an increase of $2.78 (at the midpoint of the range) due to strong underlying business growth, offset by $3.03 associated with the Q2 acquired IPR&D charges from recent business development activity:
Guidance raisedNew this quarter
Peers & ETF holders
LLY peers & ETF holders
Drug Manufacturers - GeneralMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 81,965,974 | 8.45% | $88.09B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 67,540,400 | 6.96% | $81.01B | 2026-08-07 |
| FMR LLC (Fidelity) | ▲ Buy | 28,462,475 | 2.93% | $34.14B | 2026-08-13 |
| Capital Research Global Investors | ▼ Sell | 20,873,140 | 2.15% | $25.04B | 2026-08-12 |
| Geode Capital Management, LLC | ▲ Buy | 20,310,858 | 2.09% | $24.28B | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 16,226,398 | 1.67% | $19.46B | 2026-08-13 |
| Capital World Investors | ▲ Buy | 15,902,642 | 1.64% | $19.08B | 2026-08-12 |
| JPMorgan Chase & Co | ▼ Sell | 12,598,524 | 1.30% | $15.50B | 2026-08-12 |
| Norges Bank | ▼ Sell | 11,471,413 | 1.18% | $13.76B | 2026-08-12 |
| Bank of America Corp | ▲ Buy | 11,274,243 | 1.16% | $13.52B | 2026-08-14 |
| Wellington Management Group LLP | ▼ Sell | 10,998,953 | 1.13% | $13.19B | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 8,796,866 | 0.91% | $10.55B | 2026-08-13 |
| Goldman Sachs Group Inc | ▲ Buy | 7,652,960 | 0.79% | $9.18B | 2026-08-14 |
| Fisher Asset Management, LLC | ▲ Buy | 5,063,516 | 0.52% | $6.07B | 2026-08-04 |
| Wells Fargo & Company | ▲ Buy | 4,646,119 | 0.48% | $5.57B | 2026-08-14 |
| Invesco Ltd. | ▲ Buy | 3,694,152 | 0.38% | $4.43B | 2026-08-14 |
| Janus Henderson Group plc | ▼ Sell | 4,347,394 | 0.45% | $3.98B | 2026-05-18 |
| AllianceBernstein L.P. | ▼ Sell | 4,261,385 | 0.44% | $3.92B | 2026-08-14 |
| Neuberger Berman Group LLC | ▼ Sell | 1,697,061 | 0.17% | $2.04B | 2026-08-13 |
| Citigroup Inc | ▲ Buy | 1,199,053 | 0.12% | $1.44B | 2026-08-03 |
| AQR Capital Management LLC | ▲ Buy | 1,035,605 | 0.11% | $1.24B | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 945,456 | 0.10% | $1.13B | 2026-09-02 |
| Prudential Financial Inc | ▲ Buy | 734,148 | 0.08% | $880.56M | 2026-08-12 |
| Adage Capital Partners GP, L.L.C. | ▼ Sell | 726,199 | 0.07% | $871.02M | 2026-08-14 |
| Polen Capital Management LLC | ▼ Sell | 666,912 | 0.07% | $799.91M | 2026-08-04 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Dan Newhouse | House | WA04 | ▼ Sell | $1K - $15K | 2026-07-10 | 2026-07-17 |
| Michael Rulli | House | OH06 | ▼ Sell | $1K - $15K | 2026-07-01 | 2026-08-07 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $50K - $100K | 2026-06-10 | 2026-07-02 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-04-14 | 2026-05-08 |
| Elizabeth Fletcher | House | TX07 | ▼ Sell | $1K - $15K | 2026-04-08 | 2026-05-01 |
| Byron Donalds | House | FL19 | ▲ Buy | $1K - $15K | 2026-04-02 | 2026-05-13 |
| Alan Armstrong | Senate | OK | ▼ Sell | $1K - $15K | 2026-03-27 | 2026-07-21 |
| David J. Taylor | House | OH02 | ▲ Buy | $1K - $15K | 2026-02-26 | 2026-03-06 |
| Angus King | Senate | - | ▼ Sell | $1K - $15K | 2026-02-13 | 2026-03-24 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-02-09 | 2026-02-20 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-01-16 | 2026-02-02 |
| Michael Rulli | House | OH06 | ▲ Buy | $1K - $15K | 2026-01-02 | 2026-08-07 |
| Angus King | Senate | - | ▲ Buy | $1K - $15K | 2025-12-29 | 2026-01-26 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-12-18 | 2026-01-15 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2025-12-10 | 2025-12-19 |
| Michael Rulli | House | OH06 | ▼ Sell | $1K - $15K | 2025-12-02 | 2026-08-07 |
| John Boozman | Senate | AR | ▼ Sell | $1K - $15K | 2025-11-21 | 2026-08-24 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-11-13 | 2025-12-11 |
| Shelley Moore Capito | Senate | WV | ▲ Buy | $1K - $15K | 2025-10-24 | 2025-11-04 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| John Boozman | Senate | AR | ▲ Buy | $1K - $15K | 2025-08-22 | 2025-09-12 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-08-14 | 2025-09-11 |
| David J. Taylor | House | OH02 | ▲ Buy | $15K - $50K | 2025-08-14 | 2025-09-02 |
| John Boozman | Senate | AR | ▲ Buy | $1K - $15K | 2025-08-11 | 2025-09-12 |